PMID- 15385814
OWN - NLM
STAT- MEDLINE
DCOM- 20041208
LR  - 20190713
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 78
IP  - 6
DP  - 2004 Sep 27
TI  - Correlation between human leukocyte antigen antibody production and serum 
      creatinine in patients receiving sirolimus monotherapy after Campath-1H 
      induction.
PG  - 919-24
AB  - BACKGROUND: In this study, we determined whether Campath-1H induction followed by 
      sirolimus monotherapy inhibited alloantibody production in renal transplantation. 
      Second, we evaluated the correlation between human leukocyte antigen (HLA) 
      antibody production and serum creatinine levels. METHODS: Sera were taken 1 to 24 
      months after transplantation from 24 patients treated with Campath-1H and 
      sirolimus and tested for serum creatinine and HLA-specific antibody by using flow 
      cytometry and enzyme-linked immunosorbent assay. RESULTS: Ten (42%) of the 24 
      patients treated with Campath-1H and sirolimus produced HLA antibodies. Six of 
      these 10 developed both donor-specific antibodies (DSAs) and non-donor-specific 
      antibodies (NDSAs), whereas only NDSAs were detected in the other four patients. 
      In patients with biopsy-diagnosed humoral rejection (C4d+), serum levels of both 
      DSA and NDSA significantly correlated with patient serum creatinine levels. 
      Rejection treatment successfully reduced both DSAs and NDSAs and reversed humoral 
      rejection. CONCLUSIONS: The numeric relationship between serum creatinine and DSA 
      levels suggests a causal relationship between alloantibody and transplant 
      rejection.
FAU - Cai, Junchao
AU  - Cai J
AD  - Terasaki Foundation Laboratory, Los Angeles, California, USA.
FAU - Terasaki, Paul I
AU  - Terasaki PI
FAU - Bloom, Debra D
AU  - Bloom DD
FAU - Torrealba, Jose R
AU  - Torrealba JR
FAU - Friedl, Andreas
AU  - Friedl A
FAU - Sollinger, Hans W
AU  - Sollinger HW
FAU - Knechtle, Stuart J
AU  - Knechtle SJ
LA  - eng
GR  - R01 AI50938/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (CD4 Antigens)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-D Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunosuppressive Agents)
RN  - 3A189DH42V (Alemtuzumab)
RN  - AYI8EX34EU (Creatinine)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Alemtuzumab
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antibodies, Neoplasm/*therapeutic use
MH  - Antibody Formation/*immunology
MH  - Antirheumatic Agents/therapeutic use
MH  - CD4 Antigens/immunology
MH  - Creatinine/*blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Flow Cytometry
MH  - Graft Rejection/immunology
MH  - HLA Antigens/*immunology
MH  - HLA-D Antigens/immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Kidney Transplantation/*immunology/pathology
MH  - Sirolimus/*therapeutic use
EDAT- 2004/09/24 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/24 05:00
PHST- 2004/09/24 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/24 05:00 [entrez]
AID - 00007890-200409270-00020 [pii]
AID - 10.1097/01.tp.0000134398.86243.81 [doi]
PST - ppublish
SO  - Transplantation. 2004 Sep 27;78(6):919-24. doi: 
      10.1097/01.tp.0000134398.86243.81.